NO20035056D0 - Adenosinanaloger for behandling av insulinresistenssyndrom og diabetes - Google Patents
Adenosinanaloger for behandling av insulinresistenssyndrom og diabetesInfo
- Publication number
- NO20035056D0 NO20035056D0 NO20035056A NO20035056A NO20035056D0 NO 20035056 D0 NO20035056 D0 NO 20035056D0 NO 20035056 A NO20035056 A NO 20035056A NO 20035056 A NO20035056 A NO 20035056A NO 20035056 D0 NO20035056 D0 NO 20035056D0
- Authority
- NO
- Norway
- Prior art keywords
- diabetes
- treatment
- insulin resistance
- resistance syndrome
- adenosine analogues
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01111651A EP1258247A1 (fr) | 2001-05-14 | 2001-05-14 | Analogues d'adénosine pour le traitement de le diabete et de la resistance à l' insuline |
PCT/EP2002/005301 WO2002092093A1 (fr) | 2001-05-14 | 2002-05-14 | Analogues de l'adenosine pour le traitement du syndrome de resistance a l'insuline et du diabete |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20035056D0 true NO20035056D0 (no) | 2003-11-13 |
Family
ID=8177414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20035056A NO20035056D0 (no) | 2001-05-14 | 2003-11-13 | Adenosinanaloger for behandling av insulinresistenssyndrom og diabetes |
Country Status (23)
Country | Link |
---|---|
US (1) | US20030176390A1 (fr) |
EP (2) | EP1258247A1 (fr) |
JP (1) | JP2004533448A (fr) |
KR (1) | KR20040002962A (fr) |
CN (1) | CN1518450A (fr) |
BG (1) | BG108356A (fr) |
BR (1) | BR0209650A (fr) |
CA (1) | CA2447408A1 (fr) |
CO (1) | CO5540288A2 (fr) |
CZ (1) | CZ20033079A3 (fr) |
EA (1) | EA007253B1 (fr) |
EE (1) | EE200300551A (fr) |
HR (1) | HRP20030928A2 (fr) |
HU (1) | HUP0400464A3 (fr) |
IL (1) | IL158794A0 (fr) |
MX (1) | MXPA03010336A (fr) |
NO (1) | NO20035056D0 (fr) |
NZ (1) | NZ529390A (fr) |
PL (1) | PL364573A1 (fr) |
SK (1) | SK14052003A3 (fr) |
WO (1) | WO2002092093A1 (fr) |
YU (1) | YU90203A (fr) |
ZA (1) | ZA200308777B (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GT200500281A (es) * | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0500785D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
GB0607953D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607948D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607950D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607944D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
AR060607A1 (es) | 2006-04-21 | 2008-07-02 | Novartis Ag | Derivados de purina,composiciones farmaceuticas que los contienen, metodo de preparacion y usos en enfermedades obstructivas o inflamatorias de las vias respiratorias. |
EP1889846A1 (fr) | 2006-07-13 | 2008-02-20 | Novartis AG | Dérivés de purine comme agonistes du recepteur A2a |
EP1903044A1 (fr) * | 2006-09-14 | 2008-03-26 | Novartis AG | Derivés de l'adénosine en tant qu' agonistes du récepteur A2A |
MX2009004991A (es) * | 2006-11-10 | 2009-05-20 | Novartis Ag | Derivados de monoacetato de ciclopenteno-diol. |
EP2025674A1 (fr) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament |
WO2009131196A1 (fr) * | 2008-04-24 | 2009-10-29 | 武田薬品工業株式会社 | Dérivé de pyrrolidine substituée et ses utilisations |
WO2011157827A1 (fr) | 2010-06-18 | 2011-12-22 | Sanofi | Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases |
EP2567959B1 (fr) | 2011-09-12 | 2014-04-16 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8729994D0 (en) * | 1987-12-23 | 1988-02-03 | Glaxo Group Ltd | Chemical compounds |
US5055569A (en) * | 1989-10-19 | 1991-10-08 | G. D. Searle & Co. | N-(6)-substituted adenosine compounds |
HUT61567A (en) * | 1990-12-07 | 1993-01-28 | Sandoz Ag | Process for producing new pharmaceutical compositions comprising 2'-o-alkyladenosine derivatives and for producing 6-cyclohexyl-2'-o-methyladenosinehydrate |
US6376472B1 (en) * | 1996-07-08 | 2002-04-23 | Aventis Pharmaceuticals, Inc. | Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
UA51716C2 (uk) * | 1996-07-08 | 2002-12-16 | Авентіс Фармасьютікалз Продактс Інк. | Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування |
GB9723590D0 (en) * | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
US6258793B1 (en) * | 1999-12-03 | 2001-07-10 | Cv Therapeutics, Inc. | N6 heterocyclic 5′ modified adenosine derivatives |
-
2001
- 2001-05-14 EP EP01111651A patent/EP1258247A1/fr not_active Withdrawn
-
2002
- 2002-05-14 PL PL02364573A patent/PL364573A1/xx not_active Application Discontinuation
- 2002-05-14 MX MXPA03010336A patent/MXPA03010336A/es not_active Application Discontinuation
- 2002-05-14 YU YU90203A patent/YU90203A/sh unknown
- 2002-05-14 CA CA002447408A patent/CA2447408A1/fr not_active Abandoned
- 2002-05-14 CN CNA028112393A patent/CN1518450A/zh active Pending
- 2002-05-14 EA EA200301231A patent/EA007253B1/ru not_active IP Right Cessation
- 2002-05-14 JP JP2002589010A patent/JP2004533448A/ja not_active Abandoned
- 2002-05-14 CZ CZ20033079A patent/CZ20033079A3/cs unknown
- 2002-05-14 WO PCT/EP2002/005301 patent/WO2002092093A1/fr not_active Application Discontinuation
- 2002-05-14 NZ NZ529390A patent/NZ529390A/en unknown
- 2002-05-14 IL IL15879402A patent/IL158794A0/xx unknown
- 2002-05-14 EP EP02769485A patent/EP1404338A1/fr not_active Withdrawn
- 2002-05-14 SK SK1405-2003A patent/SK14052003A3/sk unknown
- 2002-05-14 US US10/145,207 patent/US20030176390A1/en not_active Abandoned
- 2002-05-14 KR KR10-2003-7014888A patent/KR20040002962A/ko not_active Application Discontinuation
- 2002-05-14 BR BR0209650-1A patent/BR0209650A/pt not_active IP Right Cessation
- 2002-05-14 HU HU0400464A patent/HUP0400464A3/hu unknown
- 2002-05-14 EE EEP200300551A patent/EE200300551A/xx unknown
-
2003
- 2003-11-11 ZA ZA200308777A patent/ZA200308777B/en unknown
- 2003-11-12 CO CO03100204A patent/CO5540288A2/es not_active Application Discontinuation
- 2003-11-13 BG BG108356A patent/BG108356A/bg unknown
- 2003-11-13 HR HR20030928A patent/HRP20030928A2/xx not_active Application Discontinuation
- 2003-11-13 NO NO20035056A patent/NO20035056D0/no unknown
Also Published As
Publication number | Publication date |
---|---|
NZ529390A (en) | 2006-06-30 |
JP2004533448A (ja) | 2004-11-04 |
ZA200308777B (en) | 2006-04-26 |
YU90203A (sh) | 2006-08-17 |
KR20040002962A (ko) | 2004-01-07 |
EP1404338A1 (fr) | 2004-04-07 |
BG108356A (bg) | 2004-12-30 |
CA2447408A1 (fr) | 2002-11-21 |
US20030176390A1 (en) | 2003-09-18 |
HUP0400464A2 (hu) | 2004-07-28 |
PL364573A1 (en) | 2004-12-13 |
BR0209650A (pt) | 2004-07-13 |
HRP20030928A2 (en) | 2005-10-31 |
IL158794A0 (en) | 2004-05-12 |
CO5540288A2 (es) | 2005-07-29 |
MXPA03010336A (es) | 2004-03-16 |
WO2002092093A1 (fr) | 2002-11-21 |
EP1258247A1 (fr) | 2002-11-20 |
EA200301231A1 (ru) | 2004-04-29 |
CZ20033079A3 (cs) | 2004-08-18 |
EE200300551A (et) | 2004-02-16 |
CN1518450A (zh) | 2004-08-04 |
EA007253B1 (ru) | 2006-08-25 |
HUP0400464A3 (en) | 2007-03-28 |
SK14052003A3 (sk) | 2004-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL161155A0 (en) | Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors | |
NO20043733L (no) | Aryl-5-tio-Β-D-glukopyranosid-derivater og legemidler for diabetes inneholdende de samme | |
DK1183020T3 (da) | (3-trihalogenmethylphenoxy)(4-halogenphenyl) til behandling af insulinresistens og type 2-diabetes | |
NO20052009D0 (no) | Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom | |
ZA200402688B (en) | Method and composition for preventing or reducing the symptons of insulin resistance syndrome. | |
NO20030832D0 (no) | Kondenserte cykliske forbindelser og medisinsk anvendelse derav | |
DK1309324T3 (da) | Antikonvulsive derivater egnede til behandling og forebyggelse af udvikling af type II diabetes mellitus og syndrom X | |
DE60236010D1 (de) | Kalibrierung der gewebedichte in der computertomographie | |
NO20044272L (no) | Legemiddel for behandling og/eller forebyggelse av kronisk avstotning | |
AU2003297060A1 (en) | Vibratory venous and arterial oximetry sensor | |
NO20035056D0 (no) | Adenosinanaloger for behandling av insulinresistenssyndrom og diabetes | |
NO20035157D0 (no) | Lungeadministrering av kjemisk modifisert insulin | |
DE60237823D1 (de) | Medizinisches behandlungsinstrument | |
DE60322507D1 (de) | Steuerbarer katheter oder dergleichen | |
DK1581297T3 (da) | Kateter med enhedsbestanddel | |
IS7189A (is) | Sómatóstatín- eða bombesínhliðstæðusamstæður til greiningar eða meðferðar og notkun þeirra | |
HK1087103A1 (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
EE200300311A (et) | Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim | |
NO20045554L (no) | Fremgangsmate for behandling av diabetes | |
DK1417189T3 (da) | Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf | |
AU2003252182A8 (en) | Therapeutic treatment for the metabolic syndrome and type 2 diabetes | |
NO20015772L (no) | Forbindelser og fremgangsmåter for behandling av post- traumatisk stress-syndrom | |
DK1556382T3 (da) | 3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf | |
DK1355668T3 (da) | Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom | |
DK1461042T3 (da) | Anvendelse af desoxypeganin til behandling af klinisk depression |